Latest Insider Transactions at Acumen Pharmaceuticals, Inc. (ABOS)
This section provides a real-time view of insider transactions for Acumen Pharmaceuticals, Inc. (ABOS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Acumen Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Acumen Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 19
2024
|
Derek M Meisner Chief Legal Officer & Corp Sec |
SELL
Open market or private sale
|
Direct |
8,933
-7.58%
|
$26,799
$3.48 P/Share
|
|
Jan 19
2024
|
Daniel Joseph O Connell President and CEO |
SELL
Open market or private sale
|
Direct |
15,200
-2.94%
|
$45,600
$3.47 P/Share
|
|
Jan 18
2024
|
Eric Siemers Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,124
-2.59%
|
$9,372
$3.71 P/Share
|
|
Jan 18
2024
|
Matt Zuga CFO & Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,242
-1.97%
|
$12,726
$3.7 P/Share
|
|
Jan 18
2024
|
Russell Barton Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,833
-2.84%
|
$8,499
$3.73 P/Share
|
|
Jan 02
2024
|
Matt Zuga CFO & Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
106,000
+32.95%
|
-
|
|
Jan 02
2024
|
Eric Siemers Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
94,000
+43.78%
|
-
|
|
Jan 02
2024
|
Derek M Meisner Chief Legal Officer & Corp Sec |
BUY
Grant, award, or other acquisition
|
Direct |
91,000
+43.58%
|
-
|
|
Jan 02
2024
|
Russell Barton Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,000
+42.27%
|
-
|
|
Jan 02
2024
|
Daniel Joseph O Connell President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
401,000
+43.65%
|
-
|
|
Aug 17
2023
|
Jeffrey L. Ives Director |
SELL
Open market or private sale
|
Direct |
41,949
-100.0%
|
$251,694
$6.57 P/Share
|
|
Aug 17
2023
|
Jeffrey L. Ives Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,949
+50.0%
|
$0
$0.96 P/Share
|
|
Jul 21
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
5,161,290
+28.35%
|
$36,129,030
$7.75 P/Share
|
|
Jan 17
2023
|
Matt Zuga CFO & Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,500
+23.4%
|
-
|
|
Jan 17
2023
|
Derek M Meisner Chief Legal Officer & Corp Sec |
BUY
Grant, award, or other acquisition
|
Direct |
26,800
+50.0%
|
-
|
|
Jan 17
2023
|
Daniel Joseph O Connell President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
114,000
+49.42%
|
-
|
|
Jan 17
2023
|
Eric Siemers Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,700
+50.0%
|
-
|
|
Jan 17
2023
|
Russell Barton Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,700
+50.0%
|
-
|
|
Dec 29
2022
|
Matt Zuga CFO & Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+39.62%
|
$50,000
$1.19 P/Share
|
|
Nov 30
2021
|
Daniel Joseph O Connell President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,118
+29.4%
|
$4,472
$4.47 P/Share
|
|
Jul 06
2021
|
Sands Capital Ventures Discovery Fund Iii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
450,000
+11.64%
|
$6,300,000
$14.88 P/Share
|
|
Jul 06
2021
|
Sands Capital Ventures Discovery Fund Iii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,967,075
+44.15%
|
-
|
|
Jul 06
2021
|
Nathan B Fountain Director |
BUY
Open market or private purchase
|
Direct |
6,250
+50.0%
|
$100,000
$16.0 P/Share
|
|
Jul 06
2021
|
Robert D. Hardie > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,062,500
+12.24%
|
$17,000,000
$16.0 P/Share
|
|
Jul 06
2021
|
Robert D. Hardie > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
6,809,625
+47.15%
|
-
|
|
Jul 06
2021
|
Daniel Joseph O Connell President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10
-0.63%
|
$160
$16.0 P/Share
|
|
Jul 06
2021
|
Daniel Joseph O Connell President and CEO |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
35
+2.17%
|
$140
$4.47 P/Share
|
|
Jul 06
2021
|
Daniel Joseph O Connell President and CEO |
BUY
Conversion of derivative security
|
Direct |
123
+7.39%
|
-
|
|
Jul 06
2021
|
John A Stalfort Iii Director |
BUY
Conversion of derivative security
|
Indirect |
131,595
+50.0%
|
-
|
|
Jul 06
2021
|
John A Stalfort Iii Director |
BUY
Open market or private purchase
|
Direct |
35,000
+16.88%
|
$560,000
$16.0 P/Share
|
|
Jul 06
2021
|
John A Stalfort Iii Director |
BUY
Conversion of derivative security
|
Direct |
130,180
+48.66%
|
-
|
|
Jul 06
2021
|
Matt Zuga CFO & Chief Business Officer |
BUY
Conversion of derivative security
|
Direct |
26,187
+50.0%
|
-
|
|
Jul 06
2021
|
Paul B Manning > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,608,469
+49.63%
|
-
|
|
Jul 06
2021
|
Paul B Manning > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
312,500
+8.53%
|
$5,000,000
$16.0 P/Share
|
|
Jul 06
2021
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
7,895,773
+50.0%
|
-
|
|
Jul 06
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,875,000
+13.21%
|
$30,000,000
$16.0 P/Share
|